<DOC>
	<DOCNO>NCT02060929</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetics ( body medication ) intranasally ( nose ) administer esketamine use device without nasal guide healthy participant .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Intranasal Esketamine Administered With Without Nasal Guide Intranasal Device</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , single-center , single-dose , 2-way crossover ( participant may receive different intervention sequentially study 2 sequence group ) , open-label ( people know identity intervention ) study . Approximately , 14 participant enrol study . This study consist screen phase 21 day , treatment phase 3 day , follow-up phase 9-13 day . Participants randomly allocate 1 2 treatment group ( Sequence 1 2 ) . In sequence 1 , participant self-administer esketamine intranasally use device nasal guide treatment A Day 1 period 1 intranasally esketamine use device without nasal guide treatment B Day 1 period 2 . In sequence 2 , participant self-administer intranasally esketamine treatment B Day 1 period 1 intranasally esketamine treatment A Day 1 period 2 . There washout period 5 10 day treatment regimen . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , pulse oximetry , target nasal examination , nasal device questionnaire , addition evaluation , specific scale use assess safety . The study duration participant approximately 45 day .</detailed_description>
	<criteria>Agrees protocoldefined use effective contraception If woman , must negative serum human chorionic gonadotropin ( hCG ) pregnancy test screening ; negative urine pregnancy test Day 1 treatment period Body mass index ( BMI ) ( weight [ kg ] /height2 [ ] 2 ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg Blood pressure ( participant supine 5 minute ) 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function Current prior history psychiatric disorder include limited psychotic , bipolar , major depressive , anxiety disorder Clinically significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic disease , infection , hypertension vascular disorder , kidney urinary tract disturbance , sleep apnea , myasthenia gravis , illness Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center ( Day 1 ) deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12lead ECG screen admission study center ( Day 1 treatment period ) deem appropriate investigator Has abnormal deviate nasal septum 1 follow symptom : blockage 1 nostril , nasal congestion ( especially 1sided ) , frequent nosebleed , frequent sinus infection , noisy breathe sleep , facial pain , headache , postnasal drip</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Intranasal</keyword>
	<keyword>Nasal Guide</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>